Stern Alex T, Forman Stuart A
From the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Anesthesiology. 2016 Jan;124(1):89-100. doi: 10.1097/ALN.0000000000000934.
Anesthetic contact residues in γ-aminobutyric acid type A (GABAA) receptors have been identified using photolabels, including two propofol derivatives. O-propofol diazirine labels H267 in β3 and α1β3 receptors, whereas m-azi-propofol labels other residues in intersubunit clefts of α1β3. Neither label has been studied in αβγ receptors, the most common isoform in mammalian brain. In αβγ receptors, other anesthetic derivatives photolabel m-azi-propofol-labeled residues, but not βH267. The authors' structural homology model of α1β3γ2L receptors suggests that β3H267 may abut some of these sites.
Substituted cysteine modification-protection was used to test β3H267C interactions with four potent anesthetics: propofol, etomidate, alphaxalone, and R-5-allyl-1-methyl-5-(m-trifluoromethyl-diazirinylphenyl) barbituric acid (mTFD-MPAB). The authors expressed α1β3γ2L or α1β3H267Cγ2L GABAA receptors in Xenopus oocytes. The authors used voltage clamp electrophysiology to assess receptor sensitivity to γ-aminobutyric acid (GABA) and anesthetics and to compare p-chloromercuribenzenesulfonate modification rates with GABA versus GABA plus anesthetics.
Enhancement of low GABA (eliciting 5% of maximum) responses by equihypnotic concentrations of all four anesthetics was similar in α1β3γ2L and α1β3H267Cγ2L receptors (n > 3). Direct activation of α1β3H267Cγ2L receptors, but not α1β3γ2L, by mTFD-MPAB and propofol was significantly greater than the other anesthetics. Modification of β3H267C by p-chloromercuribenzenesulfonate (n > 4) was rapid and accelerated by GABA. Only mTFD-MPAB slowed β3H267C modification (approximately twofold; P = 0.011).
β3H267 in α1β3γ2L GABAA receptors contacts mTFD-MPAB, but not propofol. The study results suggest that β3H267 is near the periphery of one or both transmembrane intersubunit (α+/β- and γ+/β-) pockets where both mTFD-MPAB and propofol bind.
已使用光标记物(包括两种丙泊酚衍生物)鉴定了γ-氨基丁酸A型(GABAA)受体中的麻醉接触残基。邻丙泊酚二氮杂环丙烷标记β3和α1β3受体中的H267,而间位叠氮基丙泊酚标记α1β3亚基间裂隙中的其他残基。在哺乳动物大脑中最常见的亚型αβγ受体中,尚未对这两种标记物进行研究。在αβγ受体中,其他麻醉衍生物可光标记间位叠氮基丙泊酚标记的残基,但不能标记βH267。作者构建的α1β3γ2L受体的结构同源模型表明,β3H267可能与其中一些位点相邻。
采用半胱氨酸取代修饰-保护法来检测β3H267C与四种强效麻醉剂的相互作用:丙泊酚、依托咪酯、阿法沙龙和R-5-烯丙基-1-甲基-5-(间三氟甲基二氮杂环丙烷苯基)巴比妥酸(mTFD-MPAB)。作者在非洲爪蟾卵母细胞中表达α1β3γ2L或α1β3H267Cγ2L GABAA受体。作者使用电压钳电生理学来评估受体对γ-氨基丁酸(GABA)和麻醉剂的敏感性,并比较对氯汞苯磺酸盐对GABA与GABA加麻醉剂的修饰率。
在α1β3γ2L和α1β3H267Cγ2L受体中(n>3),等催眠浓度的所有四种麻醉剂对低浓度GABA(引发最大反应的5%)反应的增强作用相似。mTFD-MPAB和丙泊酚对α1β3H267Cγ2L受体的直接激活作用显著大于其他麻醉剂,但对α1β3γ2L受体无此作用。对氯汞苯磺酸盐对β3H267C的修饰(n>4)迅速,且GABA可加速修饰。只有mTFD-MPAB减缓了β3H267C的修饰(约两倍;P=0.011)。
α1β3γ2L GABAA受体中的β3H267与mTFD-MPAB接触,但不与丙泊酚接触。研究结果表明,β3H267靠近一个或两个跨膜亚基间(α+/β-和γ+/β-)口袋的周边,mTFD-MPAB和丙泊酚均可结合于此。